Table 3. The relationship between components of inflammatory cell infiltrate of patients with high grade inflammatory cell infiltrate primary operable invasive ductal breast cancer and cancer-specific survival.

	Univariate survival analysis		Multivariate survival analysis
	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Innate immune response
Tumour neutrophil infiltrate (Low/high)	1.78 (1.09–2.90)	0.020		0.800
Tumour macrophage infiltrate (tertiles)	0.71 (0.51–0.98)	0.035		0.170
Adaptive immune response
Tumour lymphocyte infiltrate (Low/high)	0.13 (0.07–0.23)	<0.001	0.21 (0.20–0.47)	<0.001
Tumour plasma cell infiltrate (Low/high)	5.54 (3.24–9.46)	<0.001		0.956
Tumour lymphocyte infiltrate/Tumour plasma cell infiltrate ratio (tertiles)	0.33 (0.22–0.48)	<0.001		0.330
Tumour CD4+ T-lymphocytic infiltrate (tertiles)	0.96 (0.71–1.29)	0.780
Tumour CD8+ T-lymphocytic infiltrate (<2/⩾2)	0.89 (0.32–2.43)	0.813
Tumour CD8+ T-lymphocytic infiltrate (tertiles)	0.55 (0.40–0.76)	<0.001		0.597
Tumour CD20+ B-lymphocytic infiltrate (>5)	0.85 (0.50–1.45)	0.555
Tumour CD20+ B-lymphocytic infiltrate (tertiles)	0.91 (0.66–1.24)	0.534
Tumour CD138+ B-lymphocytic infiltrate (tertiles)	1.92 (1.41–2.62)	<0.001		0.422
Tumour CD8+ infiltrate/Tumour CD138+ infiltrate ratio (tertiles)	0.40 (0.27–0.59)	<0.001	0.46 (0.30–0.70)	<0.001